Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped CHU Lyon will join as a participating center (and as national French coordinator) as a part of the BEV-IP study ongoing study EudraCT-number 2014-004257-14.

Conditions

Colorectal Carcinomatosis

Interventions

PROCEDURE: Cytoreductive surgery combined with HIPEC
DRUG: bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).

Sponsor

Hospices Civils de Lyon